Value investor Seth Klarman disclosed in a recent 13G filing that it tendered all of its 8.7 million stake in Cascadian Therapeutics Inc. (CASC). Cascadian shareholders received a tender offer from Seattle Genetics for $10 a share at the end of January. CASC shares were trading at $3.82 at the end of December. This is another successful biotech investment for Seth Klarman’s Baupost.
Insider Monkey analyzed historical stock picks of Seth Klarman covering the 2002-2016 period. Our analysis showed that Klarman’s biotech stock picks were better than a lot of famous biotech hedge fund managers. You can sign up for our monthly newsletter to find out the details of our Klarman analysis. Alternatively you can get free email alerts whenever we publish an article about Baupost by submitting your email address below:
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|The Baupost Group||0||0||0||0||0||0%|
|Baupost Group GP||0||0||0||0||0||0%|
|Seth A. Klarman||0||0||0||0||0||0%|
Page 1 of 5 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
the Securities Exchange Act of 1934
(Title of Class of Securities)
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
The remainder of this cover page shall be filled out for a reporting person’s
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
information required in the remainder of this cover page shall not be deemed to
be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the